{
    "2019-03-27": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Cancer-Fighting Stocks to Boost Portfolio Gains",
                "features": {
                    "keywords": [
                        "Cancer-Fighting",
                        "Portfolio Gains"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Lilly (LLY) Signs New Immunology Deal With Private Biotech",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Immunology",
                        "Deal",
                        "Biotech"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",
                "features": {
                    "keywords": [
                        "FDA",
                        "Novartis",
                        "Jazz",
                        "Late-Stage Data",
                        "Sleep Disorder Drug",
                        "Genfit IPO"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Better Buy: Eli Lilly vs. GlaxoSmithKline",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "GlaxoSmithKline",
                        "Better Buy"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}